奥马珠单抗治疗H1抗组胺药无应答的慢性自发性荨麻疹患者:IV期开放标签SUNRISE研究结果
这项法国前瞻性、开放标签、IV期研究纳入136例H1抗组胺药无应答的成人慢性自发性荨麻疹患者,每4周皮下注射奥马珠单抗300 mg共12周。第12周74.6%患者达到疾病控制(UCT评分≥12),67.7%患者疾病控制良好(UAS7≤6);UCT与UAS7高度负相关(Spearman相关系数-0.839)。
要点
- 第12周74.6%患者达到疾病控制(UCT评分≥12),67.7%患者UAS7≤6。
- UCT评分与UAS7在第12周呈强负相关(Spearman相关系数-0.839)。
- 基线d-二聚体升高的9例中8例第12周为应答者(UAS7≤6),但作者认为d-二聚体不宜用于长期预后监测。
核心结论
- 奥马珠单抗对H1抗组胺药无应答的慢性自发性荨麻疹患者有效。
- 荨麻疹控制试验(UCT)是可靠的疾病评估工具,其评分与UAS7相关性良好。
- 本研究不支持d-二聚体用于监测成人荨麻疹的长期疾病预后,但它可能提示对奥马珠单抗应答的患者。
研究设计与样本
- 前瞻性、开放标签、IV期研究,在法国成人慢性自发性荨麻疹患者中开展。
- 纳入H1抗组胺药治疗无应答的患者136例,按1:2分层(伴血管性水肿:不伴血管性水肿)。
- 干预为奥马珠单抗300 mg皮下注射,每4周一次,共12周。
- 评估包括UCT、UAS7、血管性水肿活动评分和d-二聚体水平(探索性目标)。
主要发现
- 第12周74.6%的患者达到疾病控制(UCT评分≥12,主要终点)。
- 第12周67.7%的患者疾病控制良好(UAS7≤6)。
- 第12周UCT评分与UAS7呈强负相关(Spearman相关系数-0.839)。
- 基线平均血浆d-二聚体浓度为1002.1 ng mL-1,第8周明显下降至455 ng mL-1。
- 基线d-二聚体浓度极高(>3000 ng mL-1)的9例患者中,8例在第12周为应答者(UAS7≤6)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Omalizumab is approved as an add-on therapy for the treatment of chronic spontaneous urticaria (CSU) in patients with inadequate response to H1-antihistamine treatment. The urticaria control test (UCT) is a reliable, concise tool developed as an alternative to the 7-day urticaria activity score (UAS7) - the standard for CSU disease activity assessment. OBJECTIVES: This prospective, open-label, phase IV study evaluated the efficacy and safety of omalizumab in French adult patients with CSU nonresponsive to H1-antihistamine treatment. MATERIALS AND METHODS: Patients [n = 136; stratified 1 : 2 (with angio-oedema : without angioedema)] received omalizumab 300 mg subcutaneously every 4 weeks for 12 weeks. Study assessments included UCT, UAS7, angio-oedema activity score and d-dimer levels (exploratory objective). RESULTS: At Week 12, 74·6% of the patients achieved disease control [UCT score ≥ 12 (primary endpoint)] and 67·7% of patients showed well-controlled disease (UAS7 ≤ 6). There was a strong negative correlation between UCT score and UAS7 at Week 12 (Spearman's correlation coefficient -0·839). Mean plasma d-dimer concentration was elevated at baseline (1002·1 ng mL-1 ) and decreased notably at Week 8 (455 ng mL-1 ). Among the nine patients with a very high baseline d-dimer concentration (> 3000 ng mL-1 ), eight were responders (UAS7 ≤ 6) at Week 12. CONCLUSIONS: Omalizumab was efficacious in patients with CSU nonresponsive to H1-antihistamines. The UCT was a reliable tool for disease assessment and the scores correlated well with UAS7. This study does not support the usefulness of d-dimer to monitor long-term disease prognosis in adult urticaria; however, it may indicate patients who respond to omalizumab.
引用
- Bérard F, Ferrier Le Bouedec MC, Bouillet L, et al. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study. Br J Dermatol. 2018. PMID: 29927483. doi:10.1111/bjd.16904
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。